hair loss with glp 1 drugs Alopecia has been reported as a possible side effect of GLP-1 receptor agonists, particularly semaglutide and tirzepatide. A new study took a closer look. Read about the findings via the link in Weight-Loss Drugs Like Wegovy Are

Recently, the newly developed drug tirzepatide, which targets both the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, was introduced to the market to treat type 2 diabetes and obesity in 2022 and 2023, respectively (Table 1)

Its a facilitator

In the case of histone H3, the peptide targeted the exposed N-terminal domain, known as a tail, which is known for undergoing post-translational modifications

Operating on a patient with an uncorrected B12 deficiency increases the risk of: Impaired wound healing and a higher chance of wound breakdown Post-operative fatigue and slower recovery, particularly if anaemia is also present Elevated homocysteine, which feeds into an already elevated DVT risk profile A sub-optimal immune response during the early wound healing phase None of these is certain to happen